This multicenter work from Japanrandomized 3200 patients to receive biodegradable polymer biolimus eluting stent(Nobori) or everolimus-eluting stent with permanent polymer (Xience / Promus). The primary end point for efficacy was any revascularizationlesion. A two year follow up the Nobori stent was non-inferior to death or myocardial infarction (7.83% versus 7.69%) and TLR (6.23% versus 5.95%). ...
The use of drug-eluting stents versus bare metal stents is controversial in some clinical situations in patients at high risk of bleeding.This study randomized 1606 patients considered at low risk of restenosis but with high risk of bleeding receiving Zotarolimus eluting stent (Endeavor) or conventional stent.The clinical characteristics were similar between the two groups with...
This randomized trial of a single center with consent obtained after randomization compared the use of bivalirudin versus heparin with the use of glycoprotein inhibitors arescue only in patients having ST segment elevation myocardial infarction.The primary efficacy endpoint was a composite of death, stroke, and myocardial revascularization of the target lesion and the primary safety...
This study is a phase 2, randomized 2:1, double blind, and placebo-controlled included 59 patients with advanced heart failure of ischemic etiology undergoing autologous mesenchymal cells derived from bone marrow through intra- myocardial injection withNoga– XPsystem. The primary end point was the change in end-systolic volume measured by MRI or CT scan at 6 months.A...
There are experimental studies suggesting that metformin admin before and during ischemia and reperfusion could help to preserve left ventricular function regardless of glycometabolic state.In observational studies, the concomitant use of metformin is associated with a lower peak CK MB and troponin.380 nondiabetic patients undergoing primary angioplasty for acute coronary syndrome study with ST segment...
This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile of Aleglitazar, compared with placebo in patients with type 2 diabetes experiencing an acute coronary syndrome. A total of 7226 patients were randomized at 12 weeks post-acute coronary event to receive Aleglitazar 150 ug or placebo. The study...
Adverse effects of statins are relatively common causing poor adherence to treatment and the need for interruption of about 10-20%.The Evolocumab is a fully human monoclonal antibody that inhibits a protein converting subtilisin/ kexin type 9 (PCSK 9); this is a protein that reduces the liver’s ability to remove LDL cholesterol from theblood.This is a...
The Global SYMPLICITY registry is a prospective, multicenter study sponsored by Medtronic to evaluate long- term renal denervation safety and effectiveness in a real-world population with refractory hypertension. It plans to prospectively include a minimum of 5000 patients with refractory hypertension in 200 centers worldwide.In the 6-month analysis of the first 1000 patients included so...
The MADIT -CRT study (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy) had shown that early intervention with cardiac resynchronization therapy plus defibrillator in patients with electrical block pattern of complete left bundle branch was associated with a significant reduction of events in a mean follow-up of 2.4 years compared with the defibrillation therapy only.In...
There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that inhibits protein converting subtilisin / kexin type 9 (PCSK9) showed lowering LDL cholesterol in phase 2 studies. The objective of this Phase 3 study was to evaluate the safety and efficacy...